6-Mercaptopurine (NSC-755) given intermittently in high doses: phase II study.
D000230:Adenocarcinoma / Q000188:drug therapy; D000740:Anemia / Q000139:chemically induced; D001855:Bone Marrow Diseases / Q000139:chemically induced; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D056486:Chemical and Drug Induced Liver Injury; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy; D015122:Mercaptopurine / Q000009:adverse effects / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy*; D012004:Rectal Neoplasms / Q000188:drug therapy; D013274:Stomach Neoplasms / Q000188:drug therapy; D013921:Thrombocytopenia / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D015122:Mercaptopurine